Cell Therapy in Chronic Ischemic Heart Disease

Inclusion Criteria: * Diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery disease (CAD) referred for CABG. * Echocardiogram-assessed LVEF between 25 and 55% (Simpson's rule). * Angina (or equivalent) functional class II to IV (Canadian Cardiovascular Society) despite maximally tolerated medical therapy. * Abnormal myocardial perfusion tests: i. Cardiac scintigraphy ii. Magnetic resonance imaging iii. Dobutamine-atropine stress-echocardiogram * Non-candidates for a percutaneous coronary intervention (PCI) due to ANY of the following: i. High risk lesion ii. Extensive lesion iii. Diffuse, small vessel disease * Non-candidates for a complete CABG, or candidates for a complete CABG in whom, according to an expert panel, there is a high probability of failure of the grafts due to the extension and severity of the disease, with diffuse, small vessel involvement. * To provide a signed, written informed consent, according to the National Guidelines for Clinical Trials. Exclusion Criteria: * Severe valve heart disease requiring surgical repair. * Serologic diagnostic of Chagas' disease. * Symptoms of heart failure, even from an ischemic etiology, in the absence of objectively documented myocardial ischemia. * Malignant ventricular arrhythmias (like VT), unless an ICD have been placed. * Any acute coronary syndrome in the past 3 months. * End-stage renal disease requiring maintenance dialysis. * History of neoplasia. * Drug or alcohol abuse. * Life expectancy below 2 years. * Enrollment in any cell therapy trial in the past 2 years.